Navigation Links
EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology
Date:12/1/2009

EpiVax, Inc. today announced a collaborative research agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) aimed at evaluating EpiVax’s proprietary Tregitope technology, which could potentially reduce detrimental immune responses to certain drugs. In the course of the Roche-EpiVax collaboration, the EpiVax Tregitope technology will be evaluated for its effect on the immunogenicity of protein therapeutics.

(Vocus) December 2, 2009 -- Together, EpiVax and Roche will carry out in silico, in vitro and in vivo experiments aimed at establishing proof of concept. Under the agreement, Roche has a nonexclusive option to use Tregitope technology in its pipeline of protein therapeutic drugs with a right to a license the technology for specific products under pre-negotiated terms.

"Roche brings a wealth of experience, clinical expertise and resources to this collaboration. Working together, it is our intent to integrate the Tregitope technology into drugs that will improve human health on a global scale,” said Dr. Anne De Groot, CEO and CSO of EpiVax

Because Tregitope uses the body’s own natural responses to induce tolerance, treatments incorporating Tregitope have the potential to be far safer than administration of protein therapeutics with systemic immunosuppressants, a clinical approach to addressing immunogenicity that is relatively common. EpiVax believes the Tregitope technology could also be used for treatment of a broad range of auto-immune disorders as well as applications in the treatment of allergy, transplant, deimmunization, animal health and chronic infectious disease.

About Tregitopes
Tregitope is a set of regulatory T-cell epitopes found in the Fc region of IgG that induce the activity of the body’s own natural regulatory T cells. When administered in conjunction with other antigens or protein immunogens, the response to these immunogens is diminished and altered if the antigen/immunogens are co-administered with Tregitopes. Preliminary in vitro and in vivo studies indicate that the modification of the immune response is due to the induction of natural T reg cells.

Examples of potentially immunogenic protein therapeutics include erythropoietin and alpha interferon, as well as antibodies that have immunosuppressive and anti-inflammatory properties such as humira and rituximab. Like vaccines, protein therapeutics can engender both cellular and humoral immune responses. Anti-drug antibodies (ADA) may neutralize the therapeutic effects of the drug and/or alter its pharmacokinetics. Since the impact of immunogenicity can be quite severe, regulatory agencies are developing new guidelines for monitoring immunogenicity and drug developers are seeking to reduce immune responses through other means such as by inducing tolerance. The Tregitope technology induces the human body’s natural tolerance mechanisms, reducing the immunogenicity of co-administered proteins. The initial discovery was published in 2008, in the journal Blood, by EpiVax CEO and CIO De Groot and Martin.

About EpiVax
EpiVax, Inc. is dedicated to merging in silico, in vitro and in vivo immunology research to generate new therapeutics as well as new vaccines for infectious diseases. T cell epitope mapping, the selection of target peptides from any protein sequence, is a powerful resource for the development of novel protein therapeutics. EpiVax research shows that peptides identified by EpiMatrix™ software are highly likely to provoke an immune response when presented to T cells; some of these epitopes were found to be regulatory T cell epitopes. Others induce inflammatory immune response, the root cause of immunogenicity problems in protein therapeutics. EpiVax tools can also be used to accurately deimmunize proteins. For more information about EpiVax and their technology platform, please visit http://www.epivax.com.

###

Read the full story at http://www.prweb.com/releases/tregitope/protein_therapeutics/prweb3283064.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix
2. WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Companys Scientific Advisory Board
3. Bio-Organic Catalyst, Inc. Forms Joint Venture With SIF ICAP Mexico S.A. de C.V. as Exclusive Distribution Hub for Central America, Mexico and Caribbean.
4. MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System
5. Boston Scientifics Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network
6. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
7. Laser technology creates new forms of metal and enhances aircraft performance
8. Surgeon Performs First Single Incision Peri-Umbilical Laparoscopic Surgery in the State of Missouri
9. Penguin Computing Forms OEM Agreement with Applied Biosystems for Scyld ClusterWare
10. Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil
11. DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology
(Date:5/25/2016)... ... May 25, 2016 , ... The Ankle Plating System ... designed to address fractures of the distal tibia and fibula. This system marks ... Plating System 3 is composed of seven plate families that span the lateral, ...
(Date:5/25/2016)... ... 2016 , ... The American Medical Informatics Association (AMIA) responded ... Coordinator for Health IT (ONC) outlining a measurement approach to interoperability that focuses ... and where it was needed. The organization of health informatics professionals said a ...
(Date:5/25/2016)... ... 25, 2016 , ... WEDI, the nation’s leading authority on the use of ... Stellar has been named by the WEDI Board of Directors as WEDI’s president and ... leader with more than 35 years of experience in healthcare, association management and organizational ...
(Date:5/25/2016)... ... 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) ... company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar Ataxia ... , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is estimated ...
Breaking Biology Technology:
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
(Date:3/15/2016)... JERUSALEM , March 15, 2016 ... Jerusalem , the technology-transfer company of the Hebrew University, ... developer of remote sensing technology of various human biological ... funding, raising $2.0 million from private investors. ... technology, based on the detection of electromagnetic emissions from ...
(Date:3/11/2016)... March 11, 2016 --> ... research report "Image Recognition Market by Technology (Pattern Recognition), ... Advertising), by Deployment Type (On-Premises and Cloud), by Industry ... published by MarketsandMarkets, the global market is expected to ... 29.98 Billion by 2020, at a CAGR of 19.1%. ...
Breaking Biology News(10 mins):